Magnesium-L-Threonate Composition for Blood-Brain Barrier Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Most magnesium compounds have low bioavailability in cognitive tissues due to their inability to cross the blood-brain barrier easily, leading to insufficient magnesium levels in the brain and impaired cognitive functions.
Innovation Solution
A composition comprising magnesium-L-threonate, such as Magtein®, combined with neurotransmitters like phosphatidylserine, citicoline, or other neurotransmitters, to enhance bioavailability and improve cognitive functions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional magnesium compounds are used, then magnesium supplementation is provided, but bioavailability in cognitive tissues is low due to inability to cross the blood-brain barrier
Solution Approach 1:
The patent changes the chemical form of magnesium from conventional compounds (oxide, sulfate, citrate) to magnesium-L-threonate, a specific chelate form that alters solubility and transport properties. This parameter change enables the magnesium to cross the blood-brain barrier effectively while maintaining supplementation functionality.
Solution Approach 2:
The invention uses magnesium-L-threonate, a composite chelate structure where magnesium is bound to L-threonine. This composite material combines the benefits of magnesium supplementation with the blood-brain barrier penetrating capabilities of the L-threonine moiety, achieving both delivery and supplementation functions.
2Quantity of substance
If conventional magnesium compounds are used, then magnesium is supplied to the body, but adverse effects on the gastrointestinal tract occur
Solution Approach 1:
By changing the chemical form to magnesium-L-threonate chelate, the patent modifies the gastrointestinal tolerance profile. The chelated form is more gentle on the GI tract compared to conventional magnesium compounds, reducing adverse effects while maintaining effective magnesium delivery to tissues.
3Reliability
If magnesium levels in the brain are increased, then cognitive functions are improved, but achieving sufficient brain magnesium levels is difficult due to blood-brain barrier limitations
Solution Approach 1:
The patent changes the transport parameters of magnesium by using the L-threonate chelate form, which has specific molecular properties that enable it to cross the blood-brain barrier. This allows sufficient magnesium levels to be achieved in the brain for cognitive improvement without being blocked by the barrier.
Solution Approach 2:
The L-threonate portion of the magnesium-L-threonate complex acts as an intermediary that facilitates blood-brain barrier penetration. This intermediary structure enables the magnesium ion to reach the brain by temporarily associating with the barrier-permeable L-threonate moiety.
Data Source
AI summary
The present composition comprises magnesium-L-threonate and a neurotransmitter such as, but not limited to phosphatidylserine and optionally, at least one of vitamin C, vitamin B6, and vitamin D3. The composition has been shown to increase at least one of memory or cognition in clinical study subjects. The present disclosure is further directed to methods of identifying and a subject with a memory or cognitive deficiency and administering a therapeutically effective amount of a formula comprising magnesium-L-threonate and a neurotransmitter to improve the memory and/or cognitive deficiency. In some implementations, the magnesium-L-threonate is Magtein®. It is also intended that any other neurotransmitter that results in a synergistic composition of the magnesium-L-threonate and the neurotransmitter by administered to improve a subject's memory and/or cognition.